| __timestamp | Intra-Cellular Therapies, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 21954000000 |
| Thursday, January 1, 2015 | 18187286 | 21203000000 |
| Friday, January 1, 2016 | 24758063 | 19945000000 |
| Sunday, January 1, 2017 | 23666957 | 21420000000 |
| Monday, January 1, 2018 | 30099855 | 22540000000 |
| Tuesday, January 1, 2019 | 64947625 | 22178000000 |
| Wednesday, January 1, 2020 | 186363444 | 22084000000 |
| Friday, January 1, 2021 | 272611040 | 20118000000 |
| Saturday, January 1, 2022 | 358782000 | 19046000000 |
| Sunday, January 1, 2023 | 409864000 | 20112000000 |
| Monday, January 1, 2024 | 21969000000 |
Unleashing the power of data
In the world of pharmaceuticals, understanding the financial dynamics of companies is crucial. Johnson & Johnson, a titan in the industry, has consistently maintained high Selling, General, and Administrative (SG&A) expenses, averaging around $21 billion annually from 2014 to 2023. This reflects their expansive global operations and robust marketing strategies. In contrast, Intra-Cellular Therapies, Inc., a smaller player, has seen its SG&A expenses grow significantly, from approximately $10 million in 2014 to over $400 million in 2023, marking a staggering 3,900% increase. This growth underscores their aggressive expansion and investment in market penetration. The data highlights the contrasting scales and strategies of these companies, offering insights into their operational priorities and market positioning. As the pharmaceutical landscape evolves, these financial trends provide a window into the strategic decisions shaping the industry's future.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Johnson & Johnson
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Walgreens Boots Alliance, Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs MannKind Corporation
Johnson & Johnson and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Johnson & Johnson vs MiMedx Group, Inc.
Biogen Inc. vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Incyte Corporation or Intra-Cellular Therapies, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Amneal Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.